- Johnson, Kelly A;
- Niu, Xin;
- Glidden, David V;
- Castillo-Mancilla, Jose R;
- Yager, Jenna;
- MaWhinney, Samantha;
- Morrow, Mary;
- Okochi, Hideaki;
- Cressey, Tim R;
- Drain, Paul K;
- Gandhi, Monica;
- Anderson, Peter L;
- Spinelli, Matthew A
From directly observed therapy studies, urine tenofovir (TFV) levels were 74% lower when taking tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate. Urine TFV remains quantifiable across a range of TAF adherence patterns, but a separate point-of-care lateral flow immunoassay with a lower TFV threshold will be needed to support TAF adherence monitoring.